The Centers for Disease Control and Prevention said Friday that Moderna Inc.’s
COVID-19 vaccine produces an allergic reaction in a small percentage of people, similar to the agency’s findings about the coronavirus vaccine developed by BioNTech SE
and Pfizer Inc.
Moderna’s stock was up 1.6% in premarket trading on Monday. There were 10 cases of anaphylaxis among the roughly 4 million doses administered between Dec. 21 and Jan. 10, according to the CDC report. Both vaccines are mRNA-based vaccines, with similar efficacy rates in clinical trials. They are the only two COVID-19 vaccines that have been authorized in the U.S. so far during the pandemic. The CDC previously recommended that health care providers prepare for the possibility of anaphylaxis among some people who get vaccinated. Moderna’s stock has soared 520.3% over the past 12 months, while the S&P 500
is up 15.6%.